Browse All Available Clinical Trials
Join Now to be Notified of New Clinical Trials
View Information and Clinical Trials for Other Conditions
Anxiety
Anxiety is a
physiological state characterized by cognitive, somatic, emotional, and behavioral components (Seligman, Walker & Rosenhan,
2001). These components combine to create the feelings that we typically recognize as fear, apprehension, or worry. Anxiety is often accompanied by
physical sensations such as heart palpitations, nausea, chest pain, shortness of breath, stomach aches, or headache. The cognitive component entails
expectation of a diffuse and certain danger. Somatically the body prepares the organism to deal with threat (known as an emergency reaction): blood
pressure and heart rate are increased, sweating is increased, bloodflow to the major muscle groups is increased, and immune and digestive system
functions are inhibited. Externally, somatic signs of anxiety may include pale skin, sweating, trembling, and pupillary dilation. Emotionally, anxiety
causes a sense of dread or panic and physically causes nausea, diarrhea, and chills. Behaviorally, both voluntary and involuntary behaviors may arise
directed at escaping or avoiding the source of anxiety and often maladaptive, being most extreme in anxiety disorders. However, anxiety is not always
pathological or maladaptive: it is a common emotion along with fear, anger, sadness, and happiness, and it has a very important function in relation
to survival.
Neural circuitry involving the amygdala and hippocampus is thought to underlie anxiety (Rosen & Schulkin, 1998). When confronted with unpleasant and
potentially harmful stimuli such as foul odors or tastes, PET-scans show increased bloodflow in the amygdala. In these studies, the participants
also reported moderate anxiety. This might indicate that anxiety is a protective mechanism designed to prevent the organism from engaging in potentially
harmful behaviors.
Generalized Anxiety Disorder
Generalized anxiety disorder (GAD) is an anxiety disorder that is characterized by excessive, uncontrollable and often irrational worry about everyday things, which is
disproportionate to the actual source of worry. This excessive worry often interferes with daily functioning, as individuals suffering GAD typically catastrophize, anticipate disaster,
and are overly concerned about everyday matters such as health issues, money, family problems, or work difficulties. They often exhibit a variety of physical symptoms, including
fatigue, headaches, muscle tension, muscle aches, difficulty swallowing, trembling, twitching, irritability, sweating, and hot flashes. These symptoms must be consistent and
on-going, persisting at least 6 months, for a formal diagnosis of GAD to be introduced. Approximately 6.8 million American adults experience GAD, affecting about twice as many
women as men.
Current Research
For current research articles click
- here
Symptoms
Although anxiety attacks are not experienced by every anxiety sufferer, they are a common symptom. Anxiety attacks usually come without warning, and
although the fear is generally irrational, the perceived danger is very real. A person experiencing an anxiety attack will often feel as if they are
about to die or pass out.
Emotional symptoms of anxiety include a fear (such as that one has a mental illness, disease or will die), they may feel the need to avoid certain
stressful sitatuons or social sitatuons due to fear of embarrassment. There may be considerable confusion and irritability when the anxiety is taking
place. Physical symptoms include hot flushes, chest pain, sudden tiredness, headaches, shortness of breath, problems digesting and nausea.
Theories
Two Factor Theory of Anxiety
Sigmund Freud recognized anxiety as a "signal of danger" and a cause of "defensive behavior". He believed we acquire anxious feelings through classical
conditioning and traumatic experiences.
We maintain anxiety through operant conditioning; when we see or encounter something associated with a previous traumatic experience, anxious feelings
resurface. We feel temporarily relieved when we avoid/remove ourselves from situations which make us anxious/fearful, known as 'negative-reinforcement',
but this only increases anxious feelings the next time we are in the same position, and we will want to escape the situation again and therefore will
not make any progress against the anxiety, only intensifying the emotions or 'fear.' Phobias can be developed this way, as well as cured using the
opposite 'positive-reinforcement' whereby instead of removal from the anxiety causing situation (which acts as a 'reward' [negative-reinforcement])
something positive can be added to the situation instead to act as a reward, like actually facing your fear and coming away from it safely. This is
known as positive reinforcement of a negative situation.
Types of Anxiety
Existential Anxiety
Theologians like Paul Tillich and psychologists like Sigmund Freud have characterized anxiety as the reaction to what Tillich called, "The trauma
of nonbeing." That is, the human comes to realize that there is a point at which he or she might cease to be (die), and their encounter with reality
becomes characterized by anxiety. Religion, according to both Tillich and Freud, then becomes a carefully crafted coping mechanism in response to this
anxiety since they redefine death as the end of only the corporal part of human personal existence, assuming an immortal soul. What then becomes of
this soul and through what criteria is the cardinal difference of various religious faiths.
Philosophical ruminations are a part of this condition, and this is part of obsessive-compulsive disorder. They are typically about sex and religion or
death. However, truly rational philosophical thinking is usually driven by a desire for a rational understanding of Ultimate Reality, rather than a
desire to avoid death.
According to Viktor Frankl, author of Man's Search for Meaning, when faced with extreme mortal dangers the very basic of all human wishes is to find a
meaning of life to combat this "trauma of nonbeing" as death is near and to succumb to it (even by suicide) seems like a way out.
The "father" of existentialism, Soren Kierkegaard, regarded all humans to be born into despair by default (in The Sickness Unto Death). Such despair was
created by having a false conception of the self. He regarded the mortal self which can exist relatively, and therefore be born or die, as the false
self. The true self was the relationship of self to God (the Absolute, or Ultimate Reality), rather than to any relative object.
Test Anxiety
Test anxiety is the uneasiness, apprehension, or nervousness felt by students who have a fear of failing an exam. Students suffering from test anxiety
may experience any of the following: the association of grades with personal worth, embarrassment by a teacher, taking a class that is beyond their
ability, fear of alienation from parents or friends, time pressures, or feeling a loss of control. Emotional, cognitive, behavioral, and physical
components can all be present in test anxiety. Sweating, dizziness, headaches, racing heartbeats, nausea, fidgeting, and drumming on a desk are all
common. An optimal level of arousal is necessary to best complete a task such as an exam; however, when the anxiety or level of arousal exceeds that
optimum, it results in a decline in performance. Because test anxiety hinges on fear of negative evaluation, debate exists as to whether test anxiety
is itself a unique anxiety disorder or whether it is a specific type of social phobia. In 2006, approximately 49% of high school students were reportedly
experiencing this condition.
While the term test anxiety refers specifically to students, many adults share the same experience with regard to their career or profession. The fear
of failing a task and being negatively evaluated for it can have a similarly negative effect on the adult.
Stranger Anxiety
Anxiety when meeting or interacting with unknown people is a common stage of development in young people.
So-called "stranger anxiety" in younger people is not a phobia in the classic sense; rather it is a developmentally appropriate fear by young children
of those who do not share a 'loved-one', caretaker or parenting role. In adults, an excessive fear of other people is not a developmentally common
stage.
Anxiety in Palliative Care
Some research has strongly suggested that treating anxiety in cancer patients improves their quality of life. The treatment generally consists of
counseling, relaxation techniques or pharmacologically with benzodiazepines.
Natural Treatments
Kava root is an effective natural treatment for short-term relief of mild anxiety. Due to recent findings regarding side effects of prolonged used
of Kava-Kava, some individuals have turned to other natural herbs such as valerian (herb) root, Chamomile, orange peel and peppermint, for example.
Diagnosis
According to the Diagnostic and Statistical Manual IV-Text Revision (DSM-IV-TR), the following criteria must be met for a person to be diagnosed with Generalised Anxiety
Disorder.
- Excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least six months, about a number of events or activities (such as work or school performance).
- The person finds it difficult to control the worry.
- The anxiety and worry are associated with three (or more) of the following six symptoms (with at least some symptoms present for more days than not for the past 6 months). Note: Only one item is required in children.
- restlessness or feeling keyed up or on edge
- being easily fatigued
- irritability
- muscle tension (difficulty falling or staying asleep, or restless unsatisfying sleep)
- difficulty concentrating or the mind going blank
- The focus of the anxiety and worry is not confined to features of an Axis I disorder, e.g., the anxiety or worry is not about having a panic attack (as in panic disorder),
being embarrassed in public (as in social phobia), being contaminated (as in obsessive-compulsive disorder), being away from home or close relatives (as
in Separation Anxiety Disorder), gaining weight (as in anorexia nervosa), having multiple physical complaints (as in somatization disorder), or having a serious
illness (as in hypochondriasis), and the anxiety and worry do not occur exclusively during post-traumatic stress disorder.
- The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
- The disturbance is not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition (e.g., hyperthyroidism)
and does not occur exclusively during a Mood Disorder, a Psychotic Disorder, or a Pervasive Developmental Disorder.
GAD-7 Screening Test
A new test has recently been introduced called the GAD-7 Screening Test which has a high rate of accuracy in screening for Generalised Anxiety Disorder. It is a self-administered
test that screens for Generalised Anxiety Disorder. These figures suggest that the 5% prevalence for GAD may be too low and that up to 20% of people may have GAD.
Prevalence
The World Health Organization's Global Burden of Disease project did not include generalised anxiety disorders. In lieu of global statistics, here are some prevalence rates from
around the world:
- Australia: 3 percent of adults
- Canada: Between 3-5 percent of adults
- Italy: 2.9 percent
- Taiwan: 0.4 percent
- United States: Approximately 6.8 million American adults, or about 3.1 percent of people age 18 and over, in a given year
Potential Causes of GAD
Some research suggests that GAD may run in families, and it may also grow worse during stress. GAD usually begins at an earlier age and symptoms may
manifest themselves more slowly than in most other anxiety disorders. Some people with GAD report onset in early adulthood, usually in response to a life
stressor. Once GAD develops, it is chronic.
Treatment
SSRIs
Pharmaceutical treatments for GAD, include selective serotonin reuptake inhibitors (SSRIs), which are antidepressants that influence brain chemistry to block the reabsorption
of serotonin in the brain. SSRIs are mainly indicated for clinical
depression, but are also effective in treating anxiety disorders. Common side effects include nausea, sexual
dysfunction, headache, diarrhea, among others. Common SSRIs perscribed for GAD include:
- fluoxetine (Prozac)
- paroxetine (Paxil)
- escitalopram (Lexapro)
Other Drugs
- imipramine (Tofranil)
- venlafaxine (Effexor)
Benzodiazepines
Benzodiazepines (or "benzos") are fast-acting sedatives that are also used to treat GAD and other anxiety disorders. These are often given in the short-term due to their nature to
become habit-forming. Side effects include drowsiness, reduced motor coordination and problems with equilibrioception. Common benzodiazepines used to treat GAD include:
- alprazolam (Xanax)
- chlordiazepoxide (Librium)
- clonazepam (Klonopin)
- diazepam (Valium)
- lorazepam (Ativan)
Cognitive Behavioral Therapy
A psychological method of treatment for GAD is cognitive behavioral therapy (CBT), which involves a therapist working with the patient to understand how thoughts and feelings
influence behavior. The goal of the therapy is to change negative thought patterns that lead to the patient's anxiety, replacing them with positive, more realistic ones. Elements
of the therapy include exposure strategies to allow the patient to gradually confront their anxieties and feel more comfortable in anxiety-provoking situations, as well as to practice
the skills they have learned. CBT can be used alone or in conjunction with medication.
GAD and Comorbid Depression
In the National Comorbidity Survey (2005), 58% of patients diagnosed with major
depression were found to have an anxiety disorder; among these patients, the rate of comorbidity
with GAD was 17.2%, and with panic disorder, 9.9%. Patients with a diagnosed anxiety disorder also had high rates of comorbid
depression, including 22.4% of patients with
social phobia, 9.4% with agoraphobia, and 2.3% with panic disorder. For many, the symptoms of both depression and anxiety are not severe enough (i.e. are subsyndromal) to
justify a primary diagnosis of either major depressive disorder (MDD) or an anxiety disorder.
Patients can also be categorized as having mixed anxiety-depressive disorder, and they are at significantly increased risk of developing full-blown
depression or anxiety. Appropriate
treatment is necessary to alleviate symptoms and prevent the emergence of more serious disease.
Accumulating evidence indicates that patients with comorbid
depression and anxiety tend to have greater illness severity and a lower treatment response than those with either
disorder alone. In addition, social function and quality of life are more greatly impaired.
In addition to coexisting with
depression, research shows that GAD often coexists with substance abuse or other conditions associated with stress, such as
irritable bowel syndrome.
Patients with physical symptoms such as
insomnia or headaches should also tell their doctors about their feelings of worry and tension. This will help the patient's
health care provider to recognize whether the person is suffering from GAD.
Controversy
The loose diagnostic criteria advanced by the DSM-IV makes it very easy for practitioners diagnose a patient with GAD. Assessment of the incidence and prevalence of GAD is
difficult, because a large proportion of people with GAD have a comorbid diagnosis, either physical or mental. The diagnosis of GAD can be challenging because the difference
between normal anxiety and GAD is not always distinct. Furthermore, the diagnostic criteria — restlessness, fatigue, difficulty concentrating, irritability, muscle tension or sleep
disturbance (difficulty falling or staying asleep, or restless unsatisfying sleep) — are common factors of human life, otherwise known as normal anxiety. Without the evidence of
the patient showing increased motor tension, autonomic hyperactivity (shortness of breath, rapid heart rate, dry mouth, cold hands, and dizziness) but not panic attacks; and
increased vigilance and scanning (feeling keyed up, increased startling, impaired concentration), anxiety is not necessarily indicative of an anxiety disorder.
(adapted from Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Generalized_anxiety_disorder and http://en.wikipedia.org/wiki/Anxiety)
Cognitive Errors, Symptom Severity, and Response to Cognitive Behavior Therapy in Older Adults with Generalized Anxiety Disorder
Authors: Caudle DD, Senior AC, Wetherell JL, Rhoades HM, Beck JG, Kunik ME, Snow AL, Wilson NL, Stanley MA.
Departments of Educational Psychology (DDC) and Psychology (ACS), University of Houston, Houston, TX; the Menninger Department of Psychiatry and
Behavioral Sciences, Baylor College of Medicine (MEK, MAS), and the Department of Medicine, Baylor College of Medicine, (MEK, NLW); the Department
of Psychiatry and Behavioral Sciences, The University of Texas Health Sciences Center, Houston, TX (DDC, HMR); the Houston Center for Quality of Care
& Utilization Studies, Health Services Research and Development Service, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX
(ACS, MEK, NLW, MAS); the Department of Psychiatry, University of California, San Diego, CA (JLW); the Veterans Affairs San Diego Health Care
System, Psychology Service (JLW); the Department of Psychology, University at Buffalo–SUNY (JGB); and the Center for Mental Health and Aging,
Department of Psychology, University of Alabama, Tuscaloosa, AL (ALS).
Objective: Recent research by Wetherell et al. investigating the differential response to group-administered cognitive behavior therapy (CBT) for
generalized anxiety disorder (GAD) in older adults found that GAD severity, homework adherence, and psychiatric comorbidity predicted statistically
significant improvement. The current study investigated whether the presence/absence of cognitive errors on separate domains of the Mini-Mental State
Exam (MMSE) predicted baseline differences in symptom severity and improvement following CBT, above and beyond already established predictors. Methods:
Baseline characteristics were investigated in a sample of 208 older patients diagnosed with GAD. Predictors of treatment response were examined in a
subsample of 65 patients who completed CBT and were included in a prior study by Wetherell et al. of response predictors. Results: Results from the
baseline sample indicated that only subjects who committed an error on the MMSE Working Memory domain exhibited increased severity in anxiety and
depressive symptoms. Results from the treatment sample indicated that an error on the MMSE Orientation domain was a significant predictor of outcome
at 6-month follow-up, while controlling for previously established predictors. Patients who committed at least one error in this domain showed decreased
response relative to patients who committed no errors. Conclusion: In this sample of older adults diagnosed with GAD, poor performance on the MMSE
Working Memory domain was associated with increased baseline anxiety and depression, while baseline performance differences on the MMSE Orientation
domain predicted outcome six months after CBT intervention.
Journal: Am J Geriatr Psychiatry. 2007 Aug;15(8):680-689
Adapted from PubMed; click here to access full journal article.
Generalized Social Anxiety Disorder and Avoidant Personality Disorder: Structural Analysis and Treatment Outcome
Authors: Huppert JD, Strunk DR, Ledley DR, Davidson JR, Foa EB.
Center for the Treatment and Study of Anxiety, Department of Psychiatry, University of Pennsylvania, School of Medicine, Philadelphia,Pennsylvania.
There has been considerable controversy about whether generalized social phobia (GSP) and avoidant personality disorder (APD) are redundant diagnostic
categories. In light of the ongoing controversy, more data are needed to help determine whether GSP and APD are independent constructs. Data were
obtained from 335 people seeking treatment for GSP at a two site clinical trial. Indicators of GSP and APD were obtained along with assessments of
demographic factors, level of functioning, and indicators of related psychopathology. Confirmatory factor analyses of indicators of GSP and APD
suggested a somewhat better fit for a two-factor solution. Comparisons of GSP patients with and without APD suggested that in addition to having more
severe social phobia symptoms, patients with APD were more depressed on a self-report measure and had more functional impairment, thereby suggesting
potential utility of the diagnostic category of APD. Furthermore, the presence of APD predicted treatment response, in that patients with APD had more
change early in treatment than those without APD. APD and GSP remain highly related constructs, and different aspects of these data support and dispute
the utility of the diagnosis of APD in GSP. Possible new directions in conceptualizing APD are discussed. Depression and Anxiety 0:1-8, 2007.
Published 2007 Wiley-Liss, Inc.
Journal: Depress Anxiety. 2007 Jul 6
Adapted from PubMed; click here to access full journal article.
Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians
Authors: Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM.
University of Kuopio, Kuopio, Finland ; Karolinska Institutet, Stockholm, Sweden ; Lilly Research Laboratories and Indiana University School of Medicine ,
Indianapolis, Ind.; and McLean Hospital/Harvard Medical School, Boston, Mass. . Dr. Dunayevich is currently affiliated with Orexigen Therapeutics, San
Diego, Calif., and Dr. Pritchett is currently affiliated with Abbott Laboratories, Abbott Park, Ill.
Objective: This study examined the efficacy and tolerability of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, for the treatment
of patients with generalized anxiety disorder (GAD). Method: Patients were >/= 18 years old and recruited from 5 European countries, the United States,
and South Africa. The study had a 9-week, multicenter, randomized, double-blind, fixed-dose, placebo-controlled, parallel-group design. A total of 513
patients (mean age = 43.8 years; 67.8% female) with a DSM-IV-defined GAD diagnosis received treatment with duloxetine 60 mg/day (N = 168), duloxetine
120 mg/day (N = 170), or placebo (N = 175). The primary efficacy measure was the Hamilton Rating Scale for Anxiety (HAM-A) total score. Secondary
measures included the Sheehan Disability Scale, HAM-A psychic and somatic anxiety factor scores, and HAM-A response, remission, and sustained improvement
rates. The study was conducted from July 2004 to September 2005. Results: Both groups of duloxetine-treated patients demonstrated significantly greater
improvements in anxiety symptom severity compared with placebo-treated patients as measured by HAM-A total score and HAM-A psychic and somatic anxiety
factor scores (p values ranged from </= .01 to </= .001). Duloxetine-treated patients had greater functional improvements in Sheehan Disability
Scale global and specific domain scores (p </= .001) than placebo-treated patients. Both duloxetine doses also resulted in significantly greater
HAM-A response, remission, and sustained improvement rates compared with placebo (p values ranged from </= .01 to </= .001). The rate of study
discontinuation due to adverse events was 11.3% for duloxetine 60 mg and 15.3% for duloxetine 120 mg versus 2.3% for placebo (p </= .001).
Conclusion: The results of this study demonstrate that duloxetine 60 mg/day and 120 mg/day were efficacious and well tolerated and thus may provide
primary care physicians with a useful pharmacologic intervention for GAD.Clinical Trials Registration: ClinicalTrials.gov identifier NCT00122824.
Journal: Prim Care Companion J Clin Psychiatry. 2007;9(2):100-107
Adapted from PubMed; click here to access full journal article.
Socioeconomic Correlates of Generalized Anxiety Disorder and Major Depression in Primary Care: The GADIS II Study (Generalized Anxiety and
Depression Impact Survey II)
Authors: Ansseau M, Fischler B, Dierick M, Albert A, Leyman S, Mignon A.
Department of Psychiatry and Medical Psychology, University of Liège, C.H.U. du Sart Tilman (B35), B‐4000 Liège, Belgium.
A previous Generalized Anxiety Disorder Impact Survey (GADIS I) performed on 15,399 Belgian patients consulting their primary care physicians, revealed
high prevalences of generalized anxiety disorder (GAD) and major depression (MD) with important regional differences. The objective of this study
(GADIS II) was to replicate previous findings and to evaluate the role of socioeconomic factors in the diagnoses of GAD and MD. A large-scale
cross-sectional survey was conducted in a random sample of 377 general practitioners distributed geographically over Belgium and Luxemburg. Each
physician was asked to screen 40 consecutive patients at predefined time periods for the presence of GAD and MD using sections of the Mini International
Neuropsychiatric Interview (MINI). Socioeconomic parameters were collected. The level of impairment was assessed using the Sheehan Disability Scale. In
a sample of 13,699 patients, point prevalences of GAD and of MD were found to be 13.4 and 11.0%, respectively. Overall, 17.8% of the population was
positive for GAD and/or MD. Both disorders were significantly more frequent in women than in men. Marked regional differences were observed with
prevalences for GAD and/or MD of 24.2% in Brussels, 22.7% in Wallonia, 13.6% in Luxemburg and 12.9% in Flanders. Several socioeconomic factors were
significantly associated with positive diagnoses: living alone, a low level of education and unemployment. However, regional differences remained
significant even after controlling for socioeconomic factors. The study confirms the high prevalence of GAD and MD in primary care and the role of
several socioeconomic and regional factors in the illnesses. Depression and Anxiety 0:1-8, 2007. (c) 2007 Wiley-Liss, Inc.
Journal: Depress Anxiety. 2007 Jun 26
Adapted from PubMed; click here to access full journal article.
Efficacy of Duloxetine in the Treatment of Generalized Anxiety Disorder in Patients with Clinically Significant Pain Symptoms
Authors: Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN.
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Anxiety disorders often are accompanied by painful physical symptoms. This report assessed the effectiveness of duloxetine in improving anxiety symptoms,
pain severity, and patient functioning in adults diagnosed with generalized anxiety disorder (GAD), who presented with clinically significant pain
symptoms. Data were pooled from two multicenter, randomized, double-blind, placebo-controlled clinical studies evaluating the efficacy of duloxetine
60-120 mg once daily compared with placebo in the treatment of GAD. The primary patient population for these analyses was patients with baseline Visual
Analog Scale (VAS) overall pain severity score >/=30. Of the 798 randomized patients that had baseline VAS scores, approximately 44.4% of GAD
patients were identified as having baseline VAS overall pain severity score >/=30 (duloxetine N=208, placebo N=146). Duloxetine-treated patients
had significantly greater improvement compared with placebo-treated patients on anxiety symptoms (measured by Hamilton Anxiety Scale total score), on
patient functioning (measured by the Sheehan Disability Scale Global Functional Impairment Score and across all Sheehan Disability Scale domains), and
on all VAS pain items. Patients achieving remission at endpoint, and patients with lower scores on the Clinical Global Impression of Improvement and
Patient Global Impression of Improvement scales had greater improvement in VAS pain severity scores. These results suggest that in patients with GAD
who present with clinically significant pain symptoms, duloxetine is effective in reducing anxiety symptoms, pain severity, and in improving patient
functioning. Depression and Anxiety 0:1-11, 2007. (c) 2007 Wiley-Liss, Inc.
Journal: Depress Anxiety. 2007 Jun 22
Adapted from PubMed; click here to access full journal article.
Pharmacotherapy of Generalized Anxiety Disorder: Results of Duloxetine Treatment from a Pooled Analysis of Three Clinical Trials
Authors: Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M.
OBJECTIVE: Duloxetine is a serotonergic noradrenergic reuptake inhibitor with demonstrated efficacy in each of three independent studies for treatment
of adults with generalized anxiety disorder (GAD). A pooled dataset from all completed trials is provided here to show the most likely clinical outcomes
associated with duloxetine treatment for GAD. Research design and methods: Data were summed at the individual patient level from three double-blind,
placebo-controlled trials of duloxetine treatment: two were 10-week flexible-dose 60120 mg/day and one was 9-week fixed dose 60 or 120 mg/day.
Inclusion/exclusion criteria were consistent across studies. MAIN OUTCOME MEASURES: Efficacy measures included the Hamilton Anxiety Scale (HAMA)
and Sheehan Disability Scale (SDS). Adverse events were queried at every visit in each study. RESULTS: Patients were randomly assigned to duloxetine
(n = 668) or placebo (n = 495) treatment. Mean age was 42.4 years; 65% were female. Duloxetine-treated patients improved significantly more from baseline
to endpoint on HAMA total score (mean = 11.1 points) compared with placebo-treated patients (mean = 8.0 points, p </= 0.001). On the SDS global
functioning score, patients in the duloxetine group had a mean improvement from baseline of 46% compared with 25% in the placebo group (p </= 0.001).
Nausea was the most common of twelve treatment-emergent adverse events that occurred in the duloxetine group. Limitations: Pooled studies were not for
long-term treatment and did not include patients with comorbid psychiatric conditions. CONCLUSIONS: In this sample of more than 1100 patients,
duloxetine was efficacious for reducing anxiety severity and for increasing patients overall role functioning in GAD.
Journal: Curr Med Res Opin. 2007 Apr 25
Adapted from PubMed; click here to access full journal article.
Memory Bias for Threat in Generalized Anxiety Disorder: The Potential Importance of Stimulus Relevance
Authors: Coles ME, Turk CL, Heimberg RG.
Department of Psychology, Binghamton University (SUNY), Binghamton, NY 13902-6000, USA. mcoles@binghamton.edu
Information processing models propose that anxious individuals are characterized by memory biases for mood-congruent threat information. However,
evidence for memory biases in generalized anxiety disorder (GAD) has been mixed at best. Given the heterogeneity of concerns in GAD, previous use of
nomothetic stimulus sets may have precluded detection of memory biases. Therefore, in order to guarantee the relevance of the stimuli used, in the
current study individuals with GAD each individually selected words that were of personal relevance to them. Using these idiographically selected words
with 23 individuals with DSM-IV GAD and 23 non-anxious controls (NACs), results showed an implicit memory bias for threat words in individuals with
GAD compared with NACs. Furthermore, there was additional evidence that individuals with GAD may also be characterized by explicit memory bias for threat
words. The magnitude of group differences for explicit recall of threat words was similar to those previously observed in panic disorder. Limitations
and future directions are discussed.
Journal: Cogn Behav Ther. 2007;36(2):65-73.
Adapted from PubMed; click here to access full journal article.
Join Now - Become a free member and get notified about studies in your area when they become available.
Browse Our Current Studies - Look over all of our current studies being conducted throughout the United States.
View Information and Clinical Trials for Other Conditions - Access all of our health-related content.